Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFlowtech Fluid. Regulatory News (FLO)

Share Price Information for Flowtech Fluid. (FLO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 112.50
Bid: 110.00
Ask: 115.00
Change: 0.00 (0.00%)
Spread: 5.00 (4.545%)
Open: 112.50
High: 0.00
Low: 0.00
Prev. Close: 112.50
FLO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Response to Cadence Offer for

19 Jun 2008 10:22

RNS Number : 0745X
Flomerics Group PLC
19 June 2008
 



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATESAUSTRALIACANADA OR JAPAN

FOR IMMEDIATE RELEASE

 

FLOMERICS GROUP PLC 

("Flomerics" or "the Company")

The Mentor Graphics Corporation ("Mentor") response to the Cadence Design Systems Inc. ("Cadence") unsolicited proposal to buy Mentor

The Board of Flomerics notes with interest the recent rejection by the Board of Mentor of Cadence's unsolicited proposal to buy Mentor

The Cadence proposal values Mentor at approximately 1.8 x historic revenue. Mentor has announced that it has reviewed the takeover proposal from Cadence and concluded that the proposed price is "insufficient to support a transaction".  The Board of Flomerics would like to reiterate to Flomerics' shareholders its own rejection of Mentor's unsolicited offer for Flomerics for the same key reason, noting with interest that Mentor is only valuing Flomerics at approximately 1.2 x historic revenue.

Enquiries: 

 

Flomerics Group PLC

Gary Carter

Keith Butcher

Tel: 020 8487 3000

Jefferies International Limited

(Financial adviser to Flomerics)

Andres Pieczanski

Sarah McNicholas

Tel: 020 7029 8000

Oriel Securities Limited 

(Nominated Adviser and Corporate Broker to Flomerics)

Andrew Edwards

Michael Shaw

Tel: 020 7710 7600

Citigate Dewe Rogerson

Ginny Pulbrook

Seb Hoyle

Tel: 020 7638 9571

Jefferies International Limited, which is authorised and regulated in the UK by The Financial Services Authority, is acting exclusively for Flomerics and no one else in connection with the offer by Mentor for Flomerics ("Mentor Offer") and, accordingly, will not be responsible to anyone other than Flomerics for providing the protections afforded to customers of Jefferies International Limited or for providing advice in relation to the Mentor Offer or in relation to the contents of this document or any transaction or arrangement or other matter referred to herein.

Oriel Securities Limited ('Oriel Securities'), which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting for Flomerics and no-one else in connection with the matters referred to herein and will not be responsible to anyone other than Flomerics for providing the protections afforded to clients of Oriel Securities or for giving advice in relation to such matters.

The Flomerics Directors, whose names are set out below, accept responsibility for the information contained in this document, save that the only responsibility accepted by them in respect of the information relating to Mentor (which has been compiled from public sources) is to ensure that such information has been correctly and fairly reproduced and presented. Subject as aforesaid, to the best of the knowledge and belief of the Flomerics Directors (who have taken all reasonable care to ensure that such is the case), the information in this document for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information. The Flomerics Directors are David W Mann (Non Executive Chairman), Gary C Carter (Chief Executive), Keith Butcher (Finance Director), Thomas R Rowbotham (Non Executive Director) and Peter R Teague (Non Executive Director).

If you are in any doubt as to the action you should take in connection with the Mentor Offer, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or other independent financial adviser duly authorised under the Financial Services and Markets Act 2000, if you are in the United Kingdom, or, if not, from another appropriately authorised independent financial adviser.

Dealing Disclosure Requirements

Under the provisions of Rule 8.3 of the Takeover Code (the 'Code'), if any person is, or becomes, 'interested' (directly or indirectly) in 1% or more of any class of 'relevant securities' of Flomerics, all 'dealings' in any 'relevant securities' of that company (including by means of an option in respect of, or a derivative referenced to, any such 'relevant securities') must be publicly disclosed by no later than 3.30 pm (London time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the Mentor Offer becomes, or is declared, unconditional as to acceptances, lapses or is otherwise withdrawn or on which the 'offer period' otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an 'interest' in 'relevant securities' of Flomerics, they will be deemed to be a single person for the purpose of Rule 8.3.

Under the provisions of Rule 8.1 of the Code, all 'dealings' in 'relevant securities' of Flomerics by a potential offeror or by Flomerics, or by any of their respective 'associates', must be disclosed by no later than 12.00 noon (London time) on the London business day following the date of the relevant transaction.

A disclosure table, giving details of the companies in whose 'relevant securities' 'dealings' should be disclosed, and the number of such securities in issue, can be found on the Takeover Panel's website at www.thetakeoverpanel.org.uk .

'Interests in securities' arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an 'interest' by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.

Terms in quotation marks are defined in the Code, which can also be found on the Panel's website. If you are in any doubt as to whether or not you are required to disclose a 'dealing' under Rule 8, you should consult the Panel.

Sources:

The enterprise value/revenue multiple used to value Flomerics is calculated in the manner set out in Appendix 3 to the Flomerics defence document in relation to the Mentor Offer dated 27 May 2008.

The enterprise value/revenue multiple used to value Mentor is calculated as follows: Enterprise value is approximately $1.6 billion on a fully diluted basis taking into account net debt of $69 million, as set out in the Cadence press release dated 17 June 2008. Mentor's enterprise value divided by the reported revenue figure for the fiscal year ended 31 January 2008 ($880 million) yields an enterprise value/revenue multiple of approximately 1.8x. 

Note to Editors

Flomerics (www.flomerics.com) is a world-leading developer of engineering simulation software and services for analysis of fluid flow, heat transfer. Flomerics' business model is drastically different from traditional analysis because its software is designed to be embedded deeply into the design process and used by mainstream design engineers, not just by analysis specialists.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RSPKKLBFVQBFBBK
Date   Source Headline
19th Jun 20245:46 pmRNSHolding(s) in Company
18th Jun 20245:42 pmRNSIssue of shares to the Employees Benefit Trust
11th Jun 202412:17 pmRNSResult of AGM
31st May 202412:19 pmRNSHolding(s) in Company
22nd May 20246:03 pmRNSHolding(s) in Company
22nd May 20247:00 amRNSExercise of Warrant, Issue of new shares & TVR
20th May 20247:00 amRNSExercise of Options and Total Voting Rights
17th May 20242:54 pmRNSNotice of AGM
9th May 20247:00 amRNSAnnual Financial Report
1st May 20247:00 amRNSHolding(s) in Company
18th Apr 20244:10 pmRNSDirector/PDMR Shareholding
27th Mar 20242:28 pmRNSClarification note regarding Dividend - REPLACE
26th Mar 20247:16 amRNS2023 Annual Unaudited Results
25th Mar 202411:44 amRNSNotice of Results
1st Feb 202410:38 amRNSDirector/PDMR Shareholding
30th Jan 20247:00 amRNSTrading update
19th Dec 20237:00 amRNSHolding(s) in Company
25th Oct 202311:42 amRNSHolding(s) in Company
31st Aug 20234:25 pmRNSBoard Update
31st Aug 20237:00 amRNSPDMRs - Director Dealings
30th Aug 20237:00 amRNS2023 Half-year report
31st Jul 20237:00 amRNSTrading update & Notice of Half-year results
13th Jun 20231:42 pmRNSResult of AGM
5th Jun 20237:00 amRNSAwards under Long-Term Incentive Plan
5th Jun 20237:00 amRNSBoard update
19th May 20237:00 amRNSAvailability of Documents & Notice of 2023 AGM
15th May 20237:00 amRNSDirector Dealing
26th Apr 20237:01 amRNSAudited Annual Financial Report FY2022
12th Apr 20237:00 amRNSDirectorate Change
12th Apr 20237:00 amRNSUnaudited Preliminary Results-year ended 31.12.22
24th Mar 20237:00 amRNSNotice of Results - revised date
9th Mar 20238:00 amRNSAnnual Results and Presentation via IMC Platform
26th Jan 20237:00 amRNSTrading Update and Notice of Results
11th Jan 20237:00 amRNSBoard changes: NED Appointment & NED Retirement
21st Dec 20224:39 pmRNSHolding(s) in Company
31st Aug 20227:00 amRNSHalf-year Report - six months ended 30 June 2022
8th Aug 20226:27 pmRNSHolding(s) in Company
4th Aug 20227:30 amRNS2022 Half-Year Results - Investor Presentation
1st Aug 20227:00 amRNSGroup Trading Update & Notice of HY1 2022 results
21st Jul 20221:03 pmRNSHolding(s) in Company
1st Jun 20222:23 pmRNSResult of AGM and Total Voting Rights
18th May 20227:00 amRNSDirector/PDMR Shareholding
5th May 20222:20 pmRNS2021 Annual Report & Notice of 2022 AGM
3rd May 20227:00 amRNSGrant of Options under Long-Term Incentive Plan
30th Mar 20221:21 pmRNSDirector/PDMR Shareholding
29th Mar 20227:00 amRNSFY2021 Results & publication of the Annual Report
25th Mar 20225:36 pmRNSHolding(s) in Company
7th Mar 20229:00 amRNSNotice of Results and Investor Presentation
21st Feb 20225:49 pmRNSHolding(s) in Company
26th Jan 20227:01 amRNSTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.